NASDAQ:CTXR Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis $0.53 -0.01 (-1.85%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.52▼$0.5750-Day Range$0.49▼$1.0252-Week Range$0.48▼$1.07Volume867,471 shsAverage Volume1.53 million shsMarket Capitalization$95.76 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Citius Pharmaceuticals alerts: Email Address Citius Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingStrong Buy3.50 Rating ScoreUpside/Downside654.7% Upside$4.00 Price TargetShort InterestHealthy6.80% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.65Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.21) to $0.09 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.37 out of 5 starsMedical Sector450th out of 910 stocksPharmaceutical Preparations Industry206th out of 426 stocks 3.8 Analyst's Opinion Consensus RatingCitius Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCitius Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Citius Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.80% of the outstanding shares of Citius Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCitius Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Citius Pharmaceuticals has recently decreased by 16.06%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCitius Pharmaceuticals does not currently pay a dividend.Dividend GrowthCitius Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTXR. Previous Next 2.6 News and Social Media Coverage News SentimentCitius Pharmaceuticals has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Citius Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 18 people have searched for CTXR on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Citius Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Citius Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Citius Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.88% of the stock of Citius Pharmaceuticals is held by institutions.Read more about Citius Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Citius Pharmaceuticals are expected to grow in the coming year, from ($0.21) to $0.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Citius Pharmaceuticals is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Citius Pharmaceuticals is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCitius Pharmaceuticals has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Citius Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Mode MobilePre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.Claim Exclusive 100% Bonus: $0.25/Share About Citius Pharmaceuticals Stock (NASDAQ:CTXR)Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Read More CTXR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTXR Stock News HeadlinesSeptember 5 at 4:30 PM | prnewswire.comCitius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5 at 8:30 AM | prnewswire.comCitius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in OncologySeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 21, 2024 | ca.finance.yahoo.comCTXR Oct 2024 2.000 callAugust 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Citius Pharmaceuticals Amid Strategic Oncology Spinout and Promising Lead Product DataAugust 13, 2024 | finanznachrichten.deTenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination with Citius Oncology, and Provides Market UpdateAugust 12, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business UpdateAugust 12, 2024 | prnewswire.comCitius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.September 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 12, 2024 | prnewswire.comCitius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming DevelopmentsAugust 9, 2024 | msn.comCitius wins FDA nod for Lymphir in cutaneous T-cell lymphomaAugust 8, 2024 | reuters.comUS FDA approves Citius' blood cancer therapyAugust 8, 2024 | prnewswire.comCitius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaAugust 5, 2024 | prnewswire.comCitius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.July 22, 2024 | finance.yahoo.comWhen Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Turn A Profit?July 20, 2024 | finanznachrichten.deEcon Corp Services DBA Investorideas.com: Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)July 10, 2024 | prnewswire.comCitius Pharmaceuticals Details Near-Term Milestones for Late-Stage CandidatesMay 29, 2024 | prnewswire.comCitius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionSee More Headlines Receive CTXR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Fiscal Year End9/30/2024Next Earnings (Estimated)1/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTXR CUSIPN/A CIK1506251 Webwww.citiuspharma.com Phone(908) 967-6677FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+654.7%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.65% Return on Assets-39.39% Debt Debt-to-Equity RatioN/A Current Ratio6.75 Quick Ratio6.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book1.10Miscellaneous Outstanding Shares180,673,000Free Float153,572,000Market Cap$95.76 million OptionableOptionable Beta1.60 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Leonard L. Mazur (Age 79)Co-Founder, CEO, Chairman & Secretary Comp: $676.88kMr. Myron Z. Holubiak (Age 77)Co-Founder & Executive Vice Chairman Comp: $641.25kDr. Myron S. Czuczman M.D. (Age 64)Executive VP & Chief Medical Officer Comp: $571.38kMr. Jaime Bartushak (Age 56)Chief Business Officer, CFO & Chief Accounting Officer Comp: $527.97kMr. Gary F. Talarico (Age 69)Executive Vice President of Operations Ms. Ilanit AllenVice President of Investor Relations & Corporate CommunicationsDr. Alan Lader Ph.D.Senior VP and Head of Clinical Operations & Quality AssuranceMr. Dhananjay G. Wadekar (Age 70)Senior Vice President of Business Strategy Mr. Kelly Creighton Ph.D.Executive Vice President of Chemistry, Manufacturing & ControlsMr. Nikolas BurlewExecutive Vice President of Quality AssuranceMore ExecutivesKey CompetitorsVistagen TherapeuticsNASDAQ:VTGNProteostasis TherapeuticsNASDAQ:PTIDaré BioscienceNASDAQ:DAREMerrimack PharmaceuticalsNASDAQ:MACKAquestive TherapeuticsNASDAQ:AQSTView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 10,156,000 shares on 8/15/2024Ownership: 5.621%Point72 Asia Singapore Pte. Ltd.Bought 201,876 shares on 8/15/2024Ownership: 0.112%Cubist Systematic Strategies LLCBought 117,754 shares on 8/14/2024Ownership: 0.065%Point72 DIFC LtdBought 49,820 shares on 8/14/2024Ownership: 0.028%Arkadios Wealth AdvisorsBought 50,000 shares on 7/29/2024Ownership: 0.083%View All Institutional Transactions CTXR Stock Analysis - Frequently Asked Questions How have CTXR shares performed this year? Citius Pharmaceuticals' stock was trading at $0.7565 at the beginning of the year. Since then, CTXR stock has decreased by 29.9% and is now trading at $0.53. View the best growth stocks for 2024 here. How were Citius Pharmaceuticals' earnings last quarter? Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) posted its earnings results on Monday, August, 12th. The company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01. When did Citius Pharmaceuticals' stock split? Shares of Citius Pharmaceuticals reverse split before market open on Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 8th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Citius Pharmaceuticals' major shareholders? Top institutional shareholders of Citius Pharmaceuticals include Armistice Capital LLC (5.62%), Point72 Asia Singapore Pte. Ltd. (0.11%), Arkadios Wealth Advisors (0.08%) and Cubist Systematic Strategies LLC (0.07%). View institutional ownership trends. How do I buy shares of Citius Pharmaceuticals? Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Citius Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Pharmaceuticals investors own include Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), SCYNEXIS (SCYX) and Aeterna Zentaris (AEZS). This page (NASDAQ:CTXR) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.